Marker Therapeutics, Inc. Common Stock

Compare this stock

MRKR Stock Report Card

Today's performance

18%

Performance

Score:

10/100

MRKR returned -20.79% in the last 12 months. Based on SPY's performance of -13.80%, its performance is below average giving it a score of 10 of 100.

Technicals

Score:

21/100

MRKR receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

Earnings

Score:

10/100

MRKR has missed earnings 6 times in the last 20 quarters.

Profit

Score:

10/100

Out of the last 20 quarters, MRKR has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

Score:

58/100

MRKR has had a higher than average amount of volatility over the last 12 months giving it a score of 57 of 100.

Marker Therapeutics, Inc. Common Stock Summary

Nasdaq / MRKR

Healthcare

Biotechnology

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

Power up your portfolio